David v. Medtronic, Inc.

237 Cal. App. 4th 734, 188 Cal. Rptr. 3d 103, 2015 Cal. App. LEXIS 506
CourtCalifornia Court of Appeal
DecidedJune 12, 2015
DocketB254914
StatusPublished
Cited by7 cases

This text of 237 Cal. App. 4th 734 (David v. Medtronic, Inc.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
David v. Medtronic, Inc., 237 Cal. App. 4th 734, 188 Cal. Rptr. 3d 103, 2015 Cal. App. LEXIS 506 (Cal. Ct. App. 2015).

Opinion

*737 Opinion

RUBIN, Acting P. J. —

When a defendant moves to dismiss a multi-defendant action for forum non conveniens, the defendant is required to establish that an alternative forum exists in which the action could be brought against all defendants. (American Cemwood. Corp. v. American Home Assurance Co. (2001) 87 Cal.App.4th 431, 433 [104 Cal.Rptr.2d 670] (American Cemwood).) If this rule is enforced without exception, an enterprising plaintiff could preclude a forum non conveniens dismissal by naming an additional defendant over whom the alternative forum could not exercise jurisdiction. The question raised by this case is whether the presence of a so-called “nominal defendant” can prevent the remaining defendants from obtaining a forum non conveniens dismissal when, in the absence of the nominal defendant, the action can and should be pursued in alternative forums. We conclude that the presence of a nominal defendant cannot defeat a forum non conveniens dismissal which should otherwise be granted.

That situation occurred in this case, and the trial court granted the forum non conveniens motion in favor of all defendants, including the nominal defendant, resulting in an effective dismissal of plaintiffs’ claims against the nominal defendant. We conclude that the trial court correctly granted the forum non conveniens dismissal in favor of all other defendants, but erred in dismissing plaintiffs’ action against the nominal defendant. Instead, the court should have severed the action against the nominal defendant and allowed it to proceed in California. We therefore affirm in part and reverse in part.

FACTUAL AND PROCEDURAL BACKGROUND

1. Allegations of the Complaint

This case is a products liability action regarding a medical device known as Infuse. The precise details of the use of Infuse, and plaintiffs’ injuries, are unnecessary to the resolution of this appeal. Broadly speaking, Infuse consists of two parts: a genetically engineered protein that stimulates bone growth (protein) and a metal cage used as a scaffold to house the protein and provide a framework for the bone growth (cage). Infuse was approved by the Food and Drug Administration (FDA) for use in a limited class of spinal fusion surgeries. Plaintiffs are 37 patients who had Infuse implanted in off-label uses that had not been approved by the FDA. These off-label uses included different classes of spinal fusion surgeries and implantation of the Infuse protein without the Infuse cage. Plaintiffs alleged injuries including, but not limited to, back pain, nerve damage, and abnormal bone growth. One plaintiff, Brandon R. David, is a California resident; the rest of the plaintiffs live in different states.

*738 Plaintiffs named multiple defendants. The first three defendants were Medtronic, Inc., and two other Medtronic entities; Medtronic is the corporation that manufactured and sold Infuse. Plaintiffs named Wyeth, Inc., and two other Wyeth-related entities; Wyeth was alleged to have developed the protein and sold it to Medtronic. While Medtronic and Wyeth do business in California, and are subject to jurisdiction here, neither is a California corporation. 1 As the Medtronic and Wyeth entities took identical positions before the trial court and this court, we refer to them collectively as Medtronic. Broadly speaking, plaintiffs allege that Medtronic is liable for their injuries on the basis that it was aware of the dangers of off-label use of Infuse, but nonetheless widely promoted its off-label use.

Finally, plaintiffs named Dr. Gary K. Michelson as a defendant. 2 Dr. Michelson was not an employee of Medtronic. However, plaintiffs allege that the cage was “invented, in part, by Dr. Michelson.” Plaintiffs’ complaint alleges that Infuse was “promoted, invented, marketed and designed, in part, by” Dr. Michelson. As we shall discuss, defendants would ultimately offer evidence that Dr. Michelson had no involvement in the manufacture or marketing of Infuse; he simply had several patents on devices that formed the basis for the Infuse cage. Dr. Michelson is a resident of Los Angeles, California. Medtronic and Dr. Michelson argue that Dr. Michelson was named as a defendant solely to keep the case in California state court.

2. Medtronic’s Three-pronged Attack

Medtronic believed that each individual plaintiff’s case against it would depend on such unique facts as the specific representations made to that plaintiff’s surgeon, and plaintiff’s medical condition before and after the surgery. The documents and witnesses to these facts would be in each plaintiff’s home state. Medtronic also believed that each plaintiff’s home state’s law would govern that plaintiff’s claim. Therefore, Medtronic sought orders requiring each plaintiff to litigate against it in his or her home state. This was done through three simultaneous motions: (1) a motion to sever each plaintiff’s case from that of the other plaintiffs; (2) a motion to dismiss the case of each plaintiff, except David (the California plaintiff), on the grounds of forum non conveniens; and (3) a motion to transfer venue of David’s case to Sacramento, where he lives.

Severance was sought on two bases. First, Medtronic argued that plaintiffs were improperly joined under Code of Civil Procedure section 378, the statute pertaining to permissive joinder. Second, Medtronic argued that, even *739 if plaintiffs were properly joined, the interests of judicial economy weighed in favor of severance within the court’s discretion under Code of Civil Procedure section 379.5. In opposition, plaintiffs argued that their claims were properly joined under the permissive joinder statute, but addressed Medtronic’s discretionary severance argument at best superficially. 3

Medtronic’s forum non conveniens motion argued that each plaintiff’s home state was an available alternative forum, and that the public and private factors considered in a forum non conveniens analysis weighed in favor of plaintiffs’ proceeding in their home states. In order to establish that the home states were available forums, Medtronic consented to jurisdiction in each plaintiff’s home state, and agreed to toll the statute of limitations for the time that this action was pending in California. 4 Dr. Michelson did not consent to jurisdiction in plaintiffs’ home states, and Medtronic made no effort to establish that jurisdiction could be established over him in those courts. Instead, Medtronic argued that the other states were available forums for this action even if they had no jurisdiction over Dr. Michelson, because Dr. Michelson was a nominal defendant whose presence should make no difference to the available forum analysis. Medtronic proffered evidence that Dr. Michelson had no involvement in the creation, design, promotion or marketing of Infuse. Plaintiffs opposed the forum non conveniens motion on the basis that Medtronic had not met its burden to establish that any alternative forum existed, because it failed to establish that any alternative forum had jurisdiction over all

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Zougub v. Robinson Helicopter Co., Inc. CA2/5
California Court of Appeal, 2025
In re Essure Product Cases
California Court of Appeal, 2023
Campofiore v. Coyote Logistics CA5
California Court of Appeal, 2022
Pilliod v. Monsanto Co.
California Court of Appeal, 2021
Delaware North Co. v. Superior Court CA2/3
California Court of Appeal, 2016

Cite This Page — Counsel Stack

Bluebook (online)
237 Cal. App. 4th 734, 188 Cal. Rptr. 3d 103, 2015 Cal. App. LEXIS 506, Counsel Stack Legal Research, https://law.counselstack.com/opinion/david-v-medtronic-inc-calctapp-2015.